hasIndication
P23161
predicate
Indicates that one entity (typically a product, treatment, or intervention) is intended, approved, or suitable for use in addressing, preventing, or managing a particular condition, purpose, or circumstance.
All labels observed (15)
| Label | Occurrences |
|---|---|
| indication | 265 |
| hasIndication canonical | 169 |
| approvedForIndication | 14 |
| hasIndicationDetail | 6 |
| hasHealthIndication | 5 |
| hasIndicationType | 5 |
| hasPrimaryIndication | 5 |
| indicationType | 5 |
| hasDrugIndication | 3 |
| hasIndicationRegion | 3 |
| hasFDALabelIndication | 2 |
| indicationSubtype | 2 |
| isIndicatedWhen | 2 |
| hasIndicationStatus | 1 |
| leadProductIndication | 1 |
Description generation (PDg)
The one-sentence description above was generated by prompting gpt-5.1 with the predicate name and this instruction.
Instruction
Given a predicate that represents a relationship or action between entities, generate a one-sentence description explaining its meaning. # Instructions Focus on describing the relationship, not the entities themselves. # Response Format Begin the description with \' Indicates...\'
Input
Predicate: hasIndication
Generated description
Indicates that one entity (typically a product, treatment, or intervention) is intended, approved, or suitable for use in addressing, preventing, or managing a particular condition, purpose, or circumstance.
Sample triples (488)
| Subject | Object |
|---|---|
| Singulair | asthma prophylaxis via predicate surface "indication" ⓘ |
| Singulair | chronic asthma management via predicate surface "indication" ⓘ |
| Singulair | exercise-induced bronchoconstriction prevention via predicate surface "indication" ⓘ |
| Singulair | seasonal allergic rhinitis via predicate surface "indication" ⓘ |
| Singulair | perennial allergic rhinitis via predicate surface "indication" ⓘ |
| maftivimab | treatment of infection caused by Zaire ebolavirus in adults via predicate surface "indication" ⓘ |
| maftivimab | treatment of infection caused by Zaire ebolavirus in children via predicate surface "indication" ⓘ |
| maftivimab | treatment of infection caused by Zaire ebolavirus in neonates born to infected mothers via predicate surface "indication" ⓘ |
| odesivimab | Ebola virus infection ⓘ |
| Inmazeb | treatment of infection caused by Zaire ebolavirus via predicate surface "indication" ⓘ |
| Array BioPharma | BRAF-mutant melanoma ⓘ |
| Array BioPharma | BRAF V600E-mutant colorectal cancer ⓘ |
| Lipitor | hypercholesterolemia via predicate surface "indication" ⓘ |
| Lipitor | mixed dyslipidemia via predicate surface "indication" ⓘ |
| Lipitor | primary prevention of cardiovascular disease via predicate surface "indication" ⓘ |
| Lipitor | secondary prevention of cardiovascular disease via predicate surface "indication" ⓘ |
| Lipitor | prevention of myocardial infarction via predicate surface "indication" ⓘ |
| Lipitor | prevention of stroke via predicate surface "indication" ⓘ |
| Lipitor | treatment of heterozygous familial hypercholesterolemia via predicate surface "indication" ⓘ |
| Lipitor | treatment of homozygous familial hypercholesterolemia via predicate surface "indication" ⓘ |
| Synagis | prevention of serious lower respiratory tract infection caused by respiratory syncytial virus ⓘ |
| Synagis | prevention of RSV disease in high-risk infants ⓘ |
| Synagis | prevention of RSV disease in high-risk young children ⓘ |
| Exelon Patch | treatment of mild to moderate dementia of the Alzheimer’s type via predicate surface "indication" ⓘ |
| Exelon Patch | treatment of mild to moderate dementia associated with Parkinson’s disease via predicate surface "indication" ⓘ |
| Namenda | moderate Alzheimer's disease via predicate surface "indication" ⓘ |
| Namenda | severe Alzheimer's disease via predicate surface "indication" ⓘ |
| Ebixa | moderate Alzheimer's disease via predicate surface "indication" ⓘ |
| Ebixa | severe Alzheimer's disease via predicate surface "indication" ⓘ |
| Axura | moderate Alzheimer's disease via predicate surface "indication" ⓘ |
| Axura | severe Alzheimer's disease via predicate surface "indication" ⓘ |
| BEACOPP regimen | advanced-stage Hodgkin lymphoma via predicate surface "indication" ⓘ |
| BEACOPP regimen | unfavorable Hodgkin lymphoma via predicate surface "indication" ⓘ |
| BEACOPP regimen | high-risk Hodgkin lymphoma via predicate surface "indication" ⓘ |
| Lynparza | ovarian cancer ⓘ |
| Lynparza | fallopian tube cancer ⓘ |
| Lynparza | primary peritoneal cancer ⓘ |
| Lynparza | breast cancer ⓘ |
| Lynparza | pancreatic cancer ⓘ |
| Lynparza | prostate cancer ⓘ |
| Lynparza | maintenance treatment of recurrent epithelial ovarian cancer via predicate surface "hasIndicationDetail" ⓘ |
| Lynparza | maintenance treatment of BRCA-mutated advanced ovarian cancer via predicate surface "hasIndicationDetail" ⓘ |
| Lynparza | treatment of germline BRCA-mutated, HER2-negative metastatic breast cancer via predicate surface "hasIndicationDetail" ⓘ |
| Lynparza | maintenance treatment of germline BRCA-mutated metastatic pancreatic adenocarcinoma via predicate surface "hasIndicationDetail" ⓘ |
| Lynparza | treatment of homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer via predicate surface "hasIndicationDetail" ⓘ |
| Farxiga | improve glycemic control in adults with type 2 diabetes via predicate surface "indication" ⓘ |
| Farxiga | reduce risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors via predicate surface "indication" ⓘ |
| Farxiga | reduce risk of cardiovascular death and hospitalization for heart failure in adults with heart failure via predicate surface "indication" ⓘ |
| Farxiga | treatment of chronic kidney disease in adults via predicate surface "indication" ⓘ |
| Farxiga | reduce risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease via predicate surface "indication" ⓘ |